Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
9-Me-BC
Also known as: 9-Methyl-β-carboline, 9-Methyl-9H-beta-carboline
9-Me-BC is a novel beta-carboline derivative studied for its potent dopaminergic neurotrophic properties. In preclinical research, it has demonstrated the ability to regenerate dopaminergic neurons and increase dendrite and synapse growth, attracting interest for potential dopamine system recovery, but it lacks any human safety data.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 2521-07-5 |
| Molecular Formula | C12H10N2 |
| Class | Other |
| Category | Nootropics |
Mechanism of Action
9-Me-BC enhances dopaminergic neuron differentiation, dendrite growth, and synapse formation through upregulation of tyrosine hydroxylase and several neurotrophic factors including BDNF, GDNF, and CDNF. It inhibits monoamine oxidase A and B (MAO-A/B), increasing dopamine availability. It also demonstrates anti-inflammatory effects by suppressing microglial activation. Uniquely, it appears to promote actual structural regeneration of dopaminergic neurons rather than simply modulating neurotransmitter levels.
Dosing Research
No established human dosing. Animal studies used approximately 0.2-0.5 mg/kg subcutaneously. Community protocols typically reference 15-30 mg/day orally for cycles of 10-20 days. Extremely limited data — all dosing is speculative extrapolation from rodent studies. Must be protected from UV light as beta-carbolines can form toxic photoproducts.
Side Effects & Risks
HIGH RISK due to near-total absence of human data. Beta-carbolines as a class have potential DNA intercalation and phototoxicity concerns — avoid UV/sun exposure during use. MAO inhibition creates tyramine interaction risk (hypertensive crisis). Unknown long-term effects on dopamine system. Potential carcinogenicity from DNA binding has not been ruled out. Strictly experimental.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.